2. Search Result
Search Result
Results for "

COX-1-IN-2

" in MedChemExpress (MCE) Product Catalog:

32

Inhibitors & Agonists

4

Natural
Products

1

Isotope-Labeled Compounds

1

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B1153
    Glafenine
    4 Publications Verification

    GlafenIN

    		 COX CFTR Apoptosis Endoplasmic Reticulum Oxidoreductase 1 (ERO1) Metabolic Disease Inflammation/Immunology
    Glafenine (Glafenin) is a non-selective, non-steroidal anti-inflammatory drug-based COX-1/COX-2 inhibitor. Glafenine exerts anti-inflammatory, anti-proliferative and anti-cell migration effects by inhibiting the arachidonic acid metabolic pathway and reducing prostaglandin synthesis. Glafenine can induce cell cycle arrest in vascular smooth muscle cells and endothelial cells and reduce the synthesis of the extracellular matrix protein Tenascin. Glafenine can be used in the research of inflammatory-related diseases, vascular restenosis and cystic fibrosis (CF) .
    Glafenine
  • HY-N0920
    Dihydrokavain

    7,8-DihydrokawaIN; 7,8-DihydrokavaIN; MarINdININ

    		 COX Cytochrome P450 Neurological Disease Inflammation/Immunology
    Dihydrokavain (7,8-Dihydrokawain) is a natural kavalactone compound. Dihydrokavain inhibits COX-1, COX-2, CYP2C9 (IC50 = 130.95 μM), CYP2C19 (IC50 = 10.05 μM) and CYP3A4 (IC50 = 78.59 μM). Dihydrokavain reduces TNFα secretion. Dihydrokavain shows analgesic and anxiolytic effects .
    Dihydrokavain
  • HY-10439
    HPGDS inhibitor 1

    		PGE synthase Inflammation/Immunology
    HPGDS inhibitor 1 is a potent, selective and orally active Hematopoietic Prostaglandin D Synthase (HPGDS) inhibitor with an IC50s of 0.6 nM and 32 nM in enzyme and cellular assays, respectively. HPGDS inhibitor 1 does not inhibit human L-PGDS, mPGES, COX-1, COX-2, or 5-LOX .
    HPGDS inhibitor 1
  • HY-14837
    Amizon

    Enisamium iodide

    		 Influenza Virus SARS-CoV Infection
    Amizon is an orally effective antiviral and anti-inflammatory agent. Amizon inhibits influenza virus replication and restricts viral RNA synthesis. Amizon reduces the mRNA expression of COX-1, COX-2, NF-κB, TGF1β, IL-1 and IL-6, and stimulates the secretion and mRNA expression of IL-10. Amizon inhibits the oxidative activity of macrophages and possesses antioxidant and free radical-scavenging activities. Amizon is applicable to research related to influenza and acute respiratory viral infections .
    Amizon
  • HY-108259
    HQL-79

    		PGE synthase Inflammation/Immunology
    HQL-79, a potent, selective and orally active human hematopoietic prostaglandin D synthase (H-PGDS) inhibitor, highly selectively inhibits the synthesis of PGD2, and acts as an anti-allergic agent, with a Kd of 0.8 μM and an IC50 of 6 μM. Shows no obvious effect on COX-1, COX-2, m-PGES, or L-PGDS .
    HQL-79
  • HY-B1153A
    Glafenine hydrochloride
    4 Publications Verification

    GlafenIN hydrochloride

    		 COX CFTR Apoptosis Endoplasmic Reticulum Oxidoreductase 1 (ERO1) Metabolic Disease Inflammation/Immunology
    Glafenine (Glafenin) hydrochloride is a non-selective, non-steroidal anti-inflammatory drug-based COX-1/COX-2 inhibitor. Glafenine hydrochloride exerts anti-inflammatory, anti-proliferative and anti-cell migration effects by inhibiting the arachidonic acid metabolic pathway and reducing prostaglandin synthesis. Glafenine hydrochloride can induce cell cycle arrest in vascular smooth muscle cells and endothelial cells and reduce the synthesis of the extracellular matrix protein Tenascin. Glafenine hydrochloride can be used in the research of inflammatory-related diseases, vascular restenosis and cystic fibrosis (CF) .
    Glafenine hydrochloride
  • HY-15028
    Otenaproxesul

    ATB-346

    		 COX Apoptosis Inflammation/Immunology
    Otenaproxesul (ATB-346), an orally active non-steroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase-1 and 2 (COX-1 and 2). Otenaproxesul possesses antiinflammatory and antinociceptive activities .
    Otenaproxesul
  • HY-B1153R
    Glafenine (Standard)

    GlafenIN (Standard)

    		 COX CFTR Apoptosis Endoplasmic Reticulum Oxidoreductase 1 (ERO1) Reference Standards Metabolic Disease Inflammation/Immunology
    Glafenine (Standard) is the analytical standard of Glafenine. This product is intended for research and analytical applications. Glafenine (Glafenin) is a non-selective, non-steroidal anti-inflammatory drug-based COX-1/COX-2 inhibitor. Glafenine exerts anti-inflammatory, anti-proliferative and anti-cell migration effects by inhibiting the arachidonic acid metabolic pathway and reducing prostaglandin synthesis. Glafenine can induce cell cycle arrest in vascular smooth muscle cells and endothelial cells and reduce the synthesis of the extracellular matrix protein Tenascin. Glafenine can be used in the research of inflammatory-related diseases, vascular restenosis and cystic fibrosis (CF) .
    Glafenine (Standard)
  • HY-159561
    COX-1-IN-2

    		COX Inflammation/Immunology
    COX-1-IN-2 (compound 5h) is an anti-inflammatory agent with potent analgesic activity. COX-1-IN-2 exhibits a significant inhibitory effect on COX-1 (IC50=38.76 nM) .
    COX-1-IN-2
  • HY-B1130
    Isoxicam

    		COX Inflammation/Immunology
    Isoxicam is an orally active nonsteroidal anti-inflammatory compound and a COX-1/COX-2 inhibitor. Isoxicam exhibits potent anti-inflammatory activity in rat models of inflammation and significantly lower ulcerogenic risk. Isoxicam can be used for the study of inflammatory diseases and rheumatic disorders .
    Isoxicam
  • HY-B1130R
    Isoxicam (Standard)

    		Reference Standards COX Inflammation/Immunology
    Isoxicam (Standard) is the analytical standard of Isoxicam (HY-B1130). This product is intended for research and analytical applications. Isoxicam is an orally active nonsteroidal anti-inflammatory compound and a COX-1/COX-2 inhibitor. Isoxicam exhibits potent anti-inflammatory activity in rat models of inflammation and significantly lower ulcerogenic risk. Isoxicam can be used for the study of inflammatory diseases and rheumatic disorders .
    Isoxicam (Standard)
  • HY-170938
    AChE-IN-82

    		Cholinesterase (ChE) Monoamine Oxidase Beta-secretase COX LOX-1 Neurological Disease
    AChE-IN-82 (compound 49) is an acetylcholinesterase (AChE) inhibitor. AChE-IN-82 inhibits eeAChE, eqBChE, hMAO-A, hMAO-B, and BACE-1 with IC50s of 0.072, 9.81, 14.52, 0.024, 2.42 μM, respectively. AChE-IN-82 inhibits COX-1, COX-2 and 5-LOX with IC50s of 60.41, 0.187, 0.18 μM, respectively. AChE-IN-82 shows an excellent neuroprotective effect by significantly reducing oxidative stress induced by H2 O2 .
    AChE-IN-82
  • HY-150550
    COX-2-IN-26

    		COX Inflammation/Immunology
    COX-2-IN-26 is a potent, selective and orally active COX-2 inhibitor with IC50 values of 10.61, 0.067, 1.96 µM for COX-1, COX-2, 15-LOX, respectively. COX-2-IN-26 shows anti-inflammatory activity. COX-2-IN-26 shows gastrointestinal safety profile .
    COX-2-IN-26
  • HY-165587
    BM-573

    		Prostaglandin Receptor Cardiovascular Disease
    BM-573 is an orally active dual thromboxane A₂ (TXA₂) modulator with an IC50 of 1.3 nM. BM-573 possesses both thromboxane synthase (TxAS) inhibition and thromboxane receptor (TP) antagonistic effects. BM-573 can completely inhibit platelet aggregation induced by Arachidonic acid (HY-109590) or U-46619 (TXA₂ analogues). BM-573 completely blocks the generation of TXB₂ (the stable metabolite of TXA₂) in human platelets and does not inhibit cyclooxygenase (COX-1/COX-2), thus avoiding interference with other prostaglandin synthesis. BM-573 has an inhibitory effect on U-46619-induced contractions in rat gastric fundus smooth muscle (ED₅₀ = 4.2 μM), but has no effect on contractions caused by PGE₂, PGF₂α, or PGI₂. BM-573 can be used in the study of atherosclerosis, myocardial infarction, pulmonary hypertension and shock .
    BM-573
  • HY-B1153AR
    Glafenine hydrochloride (Standard)

    GlafenIN hydrochloride (Standard)

    		 COX CFTR Apoptosis Endoplasmic Reticulum Oxidoreductase 1 (ERO1) Reference Standards Metabolic Disease Inflammation/Immunology
    Glafenine (hydrochloride) (Standard) is the analytical standard of Glafenine (hydrochloride). This product is intended for research and analytical applications. Glafenine (Glafenin) hydrochloride is a non-selective, non-steroidal anti-inflammatory drug-based COX-1/COX-2 inhibitor. Glafenine hydrochloride exerts anti-inflammatory, anti-proliferative and anti-cell migration effects by inhibiting the arachidonic acid metabolic pathway and reducing prostaglandin synthesis. Glafenine hydrochloride can induce cell cycle arrest in vascular smooth muscle cells and endothelial cells and reduce the synthesis of the extracellular matrix protein Tenascin. Glafenine hydrochloride can be used in the research of inflammatory-related diseases, vascular restenosis and cystic fibrosis (CF) .
    Glafenine hydrochloride (Standard)
  • HY-177319
    COX-2-IN-56

    		COX Inflammation/Immunology
    COX-2-IN-56 (example 6) is a selective COX-2 inhibitor without significantly inhibiting COX-1. COX-2-IN-56 can be used for the study of COX-2 dependent disorders, such as inflammation .
    COX-2-IN-56
  • HY-147961
    COX-2-IN-23

    		COX Inflammation/Immunology
    COX-2-IN-23 (compound 9a) is a selective COX-2 inhibitor with IC50 values of 0.28 and 20.14 μM for COX-2 and COX-1. COX-2-IN-23 has anti-inflammatory activity and low ulcerogenic activity.
    COX-2-IN-23
  • HY-15028R
    Otenaproxesul (Standard)

    ATB-346 (Standard)

    		 COX Apoptosis Reference Standards Inflammation/Immunology
    Otenaproxesul (Standard) is the analytical standard of Otenaproxesul. This product is intended for research and analytical applications. Otenaproxesul (ATB-346), an orally active non-steroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase-1 and 2 (COX-1 and 2). Otenaproxesul possesses antiinflammatory and antinociceptive activities .
    Otenaproxesul (Standard)
  • HY-150551
    COX-2-IN-27

    		COX Inflammation/Immunology
    COX-2-IN-27 is a potent and selective COX-2 inhibitor with IC50 values of 13.22, 0.045, 1.67 µM for COX-1, COX-2, 15-LOX, respectively. COX-2-IN-27 shows anti-inflammatory activity .
    COX-2-IN-27
  • HY-113807
    ZLJ-6

    		COX Lipoxygenase Inflammation/Immunology
    ZLJ-6 is a dual COX and 5-LOX inhibitor with oral activity. The IC50 values for COX-1, COX-2 and 5-LOX were 0.73, 0.31 and 0.99 μM, respectively. ZLJ-6 has anti-inflammatory and analgesic activity .
    ZLJ-6
  • HY-172790
    Cbz-(S,S)-Pro-Pro-allyl

    		COX Lipoxygenase Inflammation/Immunology
    Cbz-(S,S)-Pro-Pro-allyl (compound 1a) is a dual inhibitor of cyclooxygenase-2 and 5-lipoxygenase with IC50 values of 0.146 nM, 0.003 nM, 0.64 nM for COX-1, COX-2, 5-LOX, respectively. Cbz-(S,S)-Pro-Pro-allyl has anti-inflammatory activity .
    Cbz-(S,S)-Pro-Pro-allyl
  • HY-B0335S
    Tolfenamic acid-d4

    		COX Inflammation/Immunology Cancer
    Tolfenamic acid-d4 is the deuterium labeled Tolfenamic Acid. Tolfenamic Acid (GEA 6414) is a non-steroidal anti-inflammatory and anti-cancer agent, selectively inhibits COX-2, with an IC50 of 13.49 μM (3.53 μg/mL) in LPS-treated (COX-2) canine DH82 monocyte/macrophage cells, but shows no effect on COX-1 .
    Tolfenamic acid-d4
  • HY-N12708
    23-O-β-D-Glucopyranosyl-20-isoveratramine

    		Others Others
    23-O-β-D-Glucopyranosyl-20-isoveratramine is a potential anti-allergic agent extracted from nettles. A variety of COX-1, COX-2, 5-lipoxygenase and trypsin-like inhibitors and H1 antagonists are found in nettle extract, which can inhibit seasonal allergies, allergic rhinitis and other inflammatory diseases. and preventive effects .
    23-O-β-D-Glucopyranosyl-20-isoveratramine
  • HY-147951
    COX-2/5-LOX-IN-3

    		COX Lipoxygenase Inflammation/Immunology
    COX-2/5-LOX-IN-3 (compound 5b) is a potent and dual COX-2/5-LOX inhibitor with IC50 values of 45.73, 5.45 and 4.33 μM for COX-1, COX-2, and 5-LOX, respectively. COX-2/5-LOX-IN-3 has the potential for the research of inflammation diseases .
    COX-2/5-LOX-IN-3
  • HY-150548
    COX-2/15-LOX-IN-1

    		COX Lipoxygenase Inflammation/Immunology
    COX-2/15-LOX-IN-1 (Compound 14) is a COX-2 and 15-lipoxygenase enzyme (15-LOX) inhibitor with IC50 values of 10.65, 0.075 and 2.98 μM against COX-1, COX-2 and 15-LOX, respectively. COX-2/15-LOX-IN-1 shows anti-inflammatory activity .
    COX-2/15-LOX-IN-1
  • HY-N0920R
    Dihydrokavain (Standard)

    7,8-DihydrokawaIN (Standard); 7,8-DihydrokavaIN (Standard); MarINdININ (Standard)

    		 Reference Standards COX Cytochrome P450 Neurological Disease Inflammation/Immunology
    Dihydrokavain (Standard) (7,8-Dihydrokawain (Standard)) is the analytical standard of Dihydrokavain (HY-N0920). This product is intended for research and analytical applications. Dihydrokavain is a natural kavalactone compound. Dihydrokavain inhibits COX-1, COX-2, CYP2C9 (IC50 = 130.95 μM), CYP2C19 (IC50 = 10.05 μM) and CYP3A4 (IC50 = 78.59 μM). Dihydrokavain reduces TNFα secretion. Dihydrokavain shows analgesic and anxiolytic effects.
    Dihydrokavain (Standard)
  • HY-N9086A
    (rac)-Poriol

    5,7,4'-Trihydroxy-6-methylflavanone

    		 NO Synthase COX Interleukin Related Inflammation/Immunology
    (rac)-Poriol (5,7,4'-Trihydroxy-6-methylflavanone) exhibits antioxidant activity, and scavenges free radical DPPH with an IC50 of 0.18 µg/mL. (rac)-Poriol inhibits the LPS (HY-D1056)-induced NO generation in RAW264.7 (98.35% inhibition rate at 10 μM), and exhibits anti-inflammatory activity. (rac)-Poriol exhibits good binding affinity with iNOS, COX-1, COX-2, TNF-α, and IL-1β .
    (rac)-Poriol
  • HY-146295
    COX-2/5-LOX-IN-2

    		COX Inflammation/Immunology
    COX-2/5-LOX-IN-2 (5b) is a potent and dual inhibitor of COX-2/5-LOX. COX-2/5-LOX-IN-2 is a benzothiophen-2-yl pyrazole carboxylic acid derivative. COX-2/5-LOX-IN-2 shows the most potent analgesic and anti-inflammatory activities surpassing that of Celecoxib and Indomethacin. COX-2/5-LOX-IN-2 shows potent COX-1, COX-2 and 5-LOX inhibitory activity with IC50s of 5.40, 0.01 and 1.78 μM, respectively .
    COX-2/5-LOX-IN-2
  • HY-146294
    COX-2/5-LOX-IN-1

    		COX Inflammation/Immunology
    COX-2/5-LOX-IN-1 (compound 3a) is a potent and dual inhibitor of COX-2/5-LOX. COX-2/5-LOX-IN-1 is a benzothiophen-2-yl pyrazole carboxylic acid derivative. COX-2/5-LOX-IN-1 shows the most potent analgesic and anti-inflammatory activities surpassing that of Celecoxib and Indomethacin. COX-2/5-LOX-IN-1 shows potent COX-1, COX-2 and 5-LOX inhibitory activity with IC50s of 12.13, 0.4 and 4.96 μM, respectively .
    COX-2/5-LOX-IN-1
  • HY-118506
    BRP-7

    		FLAP Inflammation/Immunology
    BRP-7 is a 5-lipoxygenase activating protein (FLAP) inhibitor with an IC50 of 0.31 μM. BRP-7 inhibits the co-localization of 5-lipoxygenase (5-LOX) and FLAP by targeting FLAP, thereby blocking the transfer of arachidonic acid (AA) to 5-LOX and suppressing the production of leukotrienes (LTs) (IC₅₀ = 0.15 μM). BRP-7 does not inhibit cyclooxygenase (COX-1/COX-2) or microsomal prostaglandin E₂ synthase-1 (mPGES-1), and does not affect cell viability or AA release. BRP-7 exhibits significant anti-inflammatory effects in rat pleurisy and mouse peritonitis models. BRP-7 can be used for the study of inflammatory diseases .
    BRP-7
  • HY-10439R
    HPGDS inhibitor 1 (Standard)

    		Reference Standards PGE synthase Inflammation/Immunology
    HPGDS inhibitor 1 (Standard) is the analytical standard of HPGDS inhibitor 1 (HY-10439). This product is intended for research and analytical applications. HPGDS inhibitor 1 is a potent, selective and orally active Hematopoietic Prostaglandin D Synthase (HPGDS) inhibitor with an IC50s of 0.6 nM and 32 nM in enzyme and cellular assays, respectively. HPGDS inhibitor 1 does not inhibit human L-PGDS, mPGES, COX-1, COX-2, or 5-LOX .
    HPGDS inhibitor 1 (Standard)
  • HY-108259R
    HQL-79 (Standard)

    		Reference Standards PGE synthase Inflammation/Immunology
    HQL-79 (Standard) is the analytical standard of HQL-79 (HY-108259). This product is intended for research and analytical applications. HQL-79, a potent, selective and orally active human hematopoietic prostaglandin D synthase (H-PGDS) inhibitor, highly selectively inhibits the synthesis of PGD2, and acts as an anti-allergic agent, with a Kd of 0.8 μM and an IC50 of 6 μM. Shows no obvious effect on COX-1, COX-2, m-PGES, or L-PGDS .
    HQL-79 (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: